1. Home
  2. IMUX vs TLSA Comparison

IMUX vs TLSA Comparison

Compare IMUX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • TLSA
  • Stock Information
  • Founded
  • IMUX 2016
  • TLSA 2013
  • Country
  • IMUX United States
  • TLSA United Kingdom
  • Employees
  • IMUX N/A
  • TLSA N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • TLSA Health Care
  • Exchange
  • IMUX Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • IMUX 86.3M
  • TLSA 87.8M
  • IPO Year
  • IMUX N/A
  • TLSA 2000
  • Fundamental
  • Price
  • IMUX $0.94
  • TLSA $0.75
  • Analyst Decision
  • IMUX Strong Buy
  • TLSA
  • Analyst Count
  • IMUX 6
  • TLSA 0
  • Target Price
  • IMUX $12.67
  • TLSA N/A
  • AVG Volume (30 Days)
  • IMUX 946.7K
  • TLSA 1.1M
  • Earning Date
  • IMUX 02-20-2025
  • TLSA 02-18-2025
  • Dividend Yield
  • IMUX N/A
  • TLSA N/A
  • EPS Growth
  • IMUX N/A
  • TLSA N/A
  • EPS
  • IMUX N/A
  • TLSA N/A
  • Revenue
  • IMUX N/A
  • TLSA N/A
  • Revenue This Year
  • IMUX N/A
  • TLSA N/A
  • Revenue Next Year
  • IMUX N/A
  • TLSA N/A
  • P/E Ratio
  • IMUX N/A
  • TLSA N/A
  • Revenue Growth
  • IMUX N/A
  • TLSA N/A
  • 52 Week Low
  • IMUX $0.92
  • TLSA $0.41
  • 52 Week High
  • IMUX $2.11
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 38.85
  • TLSA 51.78
  • Support Level
  • IMUX $0.94
  • TLSA $0.65
  • Resistance Level
  • IMUX $1.02
  • TLSA $0.70
  • Average True Range (ATR)
  • IMUX 0.06
  • TLSA 0.05
  • MACD
  • IMUX 0.00
  • TLSA 0.01
  • Stochastic Oscillator
  • IMUX 13.58
  • TLSA 47.20

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: